- Home
- WINT vs SHPH Comparison
WINT vs SHPH Comparison
Compare WINT & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SHPH
- Stock Information
- Founded
- WINT 1992
- SHPH 2012
- Country
- WINT United States
- SHPH United States
- Employees
- WINT N/A
- SHPH N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- SHPH Health Care
- Exchange
- WINT Nasdaq
- SHPH Nasdaq
- Market Cap
- WINT 2.9M
- SHPH 2.7M
- IPO Year
- WINT 1995
- SHPH 2022
- Fundamental
- Price
- WINT $0.31
- SHPH $0.81
- Analyst Decision
- WINT Hold
- SHPH
- Analyst Count
- WINT 1
- SHPH 0
- Target Price
- WINT $7.00
- SHPH N/A
- AVG Volume (30 Days)
- WINT 1.2M
- SHPH 119.3K
- Earning Date
- WINT 11-27-2024
- SHPH 11-13-2024
- Dividend Yield
- WINT N/A
- SHPH N/A
- EPS Growth
- WINT N/A
- SHPH N/A
- EPS
- WINT N/A
- SHPH N/A
- Revenue
- WINT N/A
- SHPH N/A
- Revenue This Year
- WINT N/A
- SHPH N/A
- Revenue Next Year
- WINT N/A
- SHPH N/A
- P/E Ratio
- WINT N/A
- SHPH N/A
- Revenue Growth
- WINT N/A
- SHPH N/A
- 52 Week Low
- WINT $0.32
- SHPH $0.58
- 52 Week High
- WINT $14.75
- SHPH $4.94
- Technical
- Relative Strength Index (RSI)
- WINT 28.66
- SHPH 45.07
- Support Level
- WINT $0.33
- SHPH $0.58
- Resistance Level
- WINT $0.42
- SHPH $0.79
- Average True Range (ATR)
- WINT 0.03
- SHPH 0.07
- MACD
- WINT 0.02
- SHPH 0.02
- Stochastic Oscillator
- WINT 1.91
- SHPH 74.80
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.